

Product Description

Pioneering GTPase and Oncogene Product Development since 2010

HINT3 RABBIT PAB

Cat.#: S219848

Product Name: Anti-HINT3 Rabbit Polyclonal Antibody

Synonyms: HINT4

UNIPROT ID: Q9NQE9 (Gene Accession - NP_612638)

Background: Histidine triad proteins, such as HINT3, are nucleotide hydrolases and transferases that act

on the alpha-phosphate of ribonucleotides.

Immunogen: Synthetic peptide of human HINT3

Applications: ELISA, WB, IHC

Recommended Dilutions: IHC: 50-200;WB: 500-2000;ELISA: 5000-10000

Host Species: Rabbit

Clonality: Rabbit Polyclonal

Isotype: Immunogen-specific rabbit IgG **Purification:** Antigen affinity purification

Species Reactivity: Human

Constituents: PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol


Research Areas: Epigenetics and Nuclear Signaling

Storage & Shipping: Store at -20°C. Avoid repeated freezing and thawing




Product Description


Pioneering GTPase and Oncogene Product Development since 2010




Immunohistochemistry analysis of paraffin embedded Human liver cancer tissue using 219848(HINT3 Antibody) at a dilution of 1/60(Cytoplasm).




In comparision with the IHC on the left, the same paraffin-embedded Human liver cancer tissue is first treated with the synthetic peptide and then with 219848(Anti-HINT3 Antibody) at dilution 1/60.



The image on the left is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using 219848(Anti-HINT3 Antibody) at a dilution of 1/60.



In comparision with the IHC on the left, the same paraffin-embedded Human gastric cancer tissue is first treated with synthetic peptide and then with D260478 (Anti-HINT3 Antibody) at dilution 1/60.



Gel: 12%SDS-PAGE, Lysate: 40 μg; Lane: HepG2 cell lysate; Primary antibody: 219848(HINT3 Antibody) at dilution 1/1000; Secondary antibody: HRP-conjugated Goat anti rabbit IgG at 1/5000 dilution;

xposure time: 90 seconds



Product Description

Pioneering GTPase and Oncogene Product Development since 2010